Skip to the beginning of the images gallery

Celgene (B)

Reference: HBS-218099-E
Number of pages: 2
Publication Date: Mar 21, 2018
Fecha de edición: May 8, 2018
Source: HBSP (USA)
Type of Document: Case
Industry Setting: Biotechnology

Grouped product items
Format	Language	Reference	Use	Qty	Price
pdf	English	HBS-218099-E			As low as €5.74

You already have a subscription

To order please contact the person in charge of academic purchases in your university.

You'll be able to order once your profile has been validated.

Description

In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.

Keywords

Decision making Finance Growth Hedge funds Investments Stocks Valuation